BioMarin Pharmaceutical (NASDAQ: BMRN) has recently received a number of price target changes and ratings updates:
- 9/9/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
- 9/5/2024 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $100.00 price target on the stock.
- 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Scotiabank from $86.00 to $95.00. They now have a “sector perform” rating on the stock.
- 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at JPMorgan Chase & Co. from $111.00 to $120.00. They now have an “overweight” rating on the stock.
- 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Piper Sandler from $107.00 to $122.00. They now have an “overweight” rating on the stock.
- 9/5/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Truist Financial Co. from $140.00 to $118.00. They now have a “buy” rating on the stock.
- 8/30/2024 – BioMarin Pharmaceutical was upgraded by analysts at William Blair to a “strong-buy” rating.
- 8/27/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $107.00 price target on the stock.
- 8/21/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Stifel Nicolaus from $112.00 to $115.00. They now have a “buy” rating on the stock.
- 8/20/2024 – BioMarin Pharmaceutical was upgraded by analysts at Sanford C. Bernstein from a “market perform” rating to an “outperform” rating. They now have a $110.00 price target on the stock, up previously from $94.00.
- 8/8/2024 – BioMarin Pharmaceutical was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Scotiabank from $85.00 to $86.00. They now have a “sector perform” rating on the stock.
- 8/6/2024 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $100.00 price target on the stock.
- 8/6/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Barclays PLC from $111.00 to $110.00. They now have an “overweight” rating on the stock.
- 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Evercore ISI from $113.00 to $115.00. They now have an “outperform” rating on the stock.
- 8/6/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at TD Cowen from $125.00 to $120.00. They now have a “buy” rating on the stock.
- 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Stifel Nicolaus from $108.00 to $112.00. They now have a “buy” rating on the stock.
- 8/5/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
- 7/30/2024 – BioMarin Pharmaceutical was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 7/25/2024 – BioMarin Pharmaceutical had its “hold” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $89.00 price target on the stock.
- 7/22/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
- 7/22/2024 – BioMarin Pharmaceutical was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
BioMarin Pharmaceutical Stock Performance
Shares of BMRN stock opened at $84.38 on Friday. The stock has a fifty day moving average price of $86.77 and a 200 day moving average price of $84.92. The stock has a market cap of $16.02 billion, a PE ratio of 78.86, a P/E/G ratio of 1.02 and a beta of 0.31. BioMarin Pharmaceutical Inc. has a 1 year low of $73.68 and a 1 year high of $99.56. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.95 and a current ratio of 3.05.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.39. The firm had revenue of $712.03 million during the quarter, compared to analysts’ expectations of $660.51 million. BioMarin Pharmaceutical had a return on equity of 6.91% and a net margin of 9.91%. Sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post 2.4 earnings per share for the current fiscal year.
Hedge Funds Weigh In On BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Read More
- Five stocks we like better than BioMarin Pharmaceutical
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Leveraged ETFs to Multiply Returns
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- 3 Healthcare Dividend Stocks to Buy
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for BioMarin Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.